A single injection – designed to provide treatment efficacy over extended periods
What makes Buvidal different?
The active ingredient in Buvidal is buprenorphine, a pharmacological molecule that will be familiar to many HCPs working in the field of opioid dependence, due to its proven ability to supress withdrawal and cravings¹.
What makes Buvidal different is its prolonged release, otherwise referred to as ‘long-acting’ properties, that slowly release the active pharmaceutical over an extended period of time, in this case over either a week or a month. The long-acting release aims to reduce the burden of daily and often supervised medication, improve the adherence to treatment and improve the quality of life.
This is achieved using Camurus’ patent-protected ‘FluidCrystal’ technology.
Smart and versatile drug delivery
FluidCrystal technology is designed to provide treatment efficacy over extended periods — with a single subcutaneous injection.
FluidCrystal comprises a lipid-based liquid with a dissolved active ingredient (in the case of Buvidal – Buprenorphine) that is injected subcutaneously. Upon contact with fluids in the tissue, the lipid solution transforms into a liquid crystalline gel, which effectively encapsulates the active ingredient.
The medicinal compound is slowly released as the liquid crystalline matrix gradually degrades in the tissue and the release can be controlled from several days to weeks or months depending on the composition. (Buvidal is available in weekly and monthly formulations).
